-
Apr 17, 2020
-
Mar 16, 2020- Top-Line Data from Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Expected in Third Quarter 2020 -
-
Jan 8, 2020Phase 1 Clinical Studies to begin in First Half of 2020
-
Dec 4, 2019IMU-856 has the potential to address one of the putative root causes of inflammatory bowel disease without impairing the immune system